{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT06049134",
            "orgStudyIdInfo": {
                "id": "2023-0590"
            },
            "secondaryIdInfos": [
                {
                    "id": "NCI-2023-07264",
                    "type": "OTHER",
                    "domain": "NCI-CTRP Clinical Trials Gov"
                }
            ],
            "organization": {
                "fullName": "M.D. Anderson Cancer Center",
                "class": "OTHER"
            },
            "briefTitle": "Immunogenicity and Clinical Efficacy of 20-valent Pneumococcal Conjugate Vaccine (PCV20) in Lymphoma Survivors After Treatment With Anti-CD20 Therapy",
            "officialTitle": "Immunogenicity and Clinical Efficacy of 20-valent Pneumococcal Conjugate Vaccine (PCV20) in Lymphoma Survivors After Treatment With Anti-CD20 Therapy",
            "therapeuticArea": [
                "Oncology and Hematology"
            ],
            "study": "immunogenicity-and-clinical-efficacy-of-valent-pneumococcal-conjugate-vaccine-in-lymphoma-survivors-after-treatment-with-anti-therapy"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-05",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2023-10-06",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2025-07-31",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2027-07-31",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2023-09-13",
            "studyFirstSubmitQcDate": "2023-09-15",
            "studyFirstPostDateStruct": {
                "date": "2023-09-21",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-05-13",
            "lastUpdatePostDateStruct": {
                "date": "2024-05-16",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "M.D. Anderson Cancer Center",
                "class": "OTHER"
            }
        },
        "oversightModule": {
            "oversightHasDmc": true,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false,
            "isUsExport": false
        },
        "descriptionModule": {
            "briefSummary": "To compare the effects of a pneumococcal vaccine called PCV20 when given as a single dose versus a boosted regimen to patients who previously received anti-CD20 therapy as treatment for B cell lymphoma.",
            "detailedDescription": "Primary Objectives:\n\n--Compare the humoral responses in terms of difference in IgG titers at 1 month from routine single dose PCV20 or a boosted PCV20 regimen in B cell lymphoma survivors who previously received treatment with anti-CD20 therapy.\n\nSecondary Objectives:\n\n* Compare the humoral responses in terms of difference in IgG titers at 3, 6 and12 from routine single dose PCV20 or a boosted PCV20 regimen in B cell lymphoma survivors who previously received treatment with anti-CD20 therapy.\n* Estimate the rate of pneumonia (all bacterial pneumonia including pneumococcal pneumonia) within a year from routine single dose PCV20 or a boosted PCV20 regimen in lymphoma survivors who previously received treatment with anti-CD 20 therapy.\n* Correlate humoral responses to development of bacterial pneumonia and pneumococcal pneumonia and with severity of this infection in lymphoma survivors within a year of vaccination."
        },
        "conditionsModule": {
            "conditions": [
                "Lymphoma"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE4"
            ],
            "designInfo": {
                "allocation": "RANDOMIZED",
                "interventionModel": "SINGLE_GROUP",
                "primaryPurpose": "SUPPORTIVE_CARE",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 30,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Arm Group A (PCV20)",
                    "type": "EXPERIMENTAL",
                    "description": "Participants will receive 1 dose of the vaccine",
                    "interventionNames": [
                        "Biological: PCV20"
                    ]
                },
                {
                    "label": "Arm Group B (PCV20)",
                    "type": "EXPERIMENTAL",
                    "description": "Participants will receive 2 doses of the vaccine",
                    "interventionNames": [
                        "Biological: PCV20"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "BIOLOGICAL",
                    "name": "PCV20",
                    "description": "Given by Injection into the muscle",
                    "armGroupLabels": [
                        "Arm Group A (PCV20)",
                        "Arm Group B (PCV20)"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0",
                    "timeFrame": "through study completion; an average of 1 year"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n1. Patients who have a history of non-Hodgkin B-cell lymphoma and whose disease has been in remission for at least 1 year.\n2. Patients who received any anti-CD20 therapy at any time during their treatment for B-cell lymphoma.\n3. Patients who are at least 18 years of age.\n4. Patients who can provide consent; no legal authorized representative will be able to provide consent on a patient's behalf.\n\nExclusion Criteria:\n\n1. Patients who have received cellular therapy, including chimeric antigen receptor T-cell therapy or any type of hematopoietic cell transplantation.\n2. Patients who have received PCV or pneumococcal polysaccharide vaccine within 5 years of screening for enrollment.\n3. Patients who are unable to attend follow-up appointments at designated times at MD Anderson.\n4. Any vulnerable population patient ((children, pregnant women, cognitively impaired adults, or prisoners)",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Fareed Khawaja, MD",
                    "role": "CONTACT",
                    "phone": "(281) 610-0253",
                    "email": "fkhawaja@mdanderson.org"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Fareed Khawaja, MD",
                    "affiliation": "M.D. Anderson Cancer Center",
                    "role": "PRINCIPAL_INVESTIGATOR"
                }
            ],
            "locations": [
                {
                    "facility": "M D Anderson Cancer Center",
                    "status": "RECRUITING",
                    "city": "Houston",
                    "state": "Texas",
                    "zip": "77030",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Fareed Khawaja, M D",
                            "role": "CONTACT",
                            "phone": "281-610-0253",
                            "email": "fkhawaja@mdanderson.org"
                        },
                        {
                            "name": "Fareed Khawaja, M D",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 29.76328,
                        "lon": -95.36327
                    }
                }
            ]
        },
        "referencesModule": {
            "seeAlsoLinks": [
                {
                    "label": "M D Anderson Cancer Center",
                    "url": "http://www.mdanderson.org"
                }
            ]
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000008223",
                    "term": "Lymphoma"
                }
            ],
            "ancestors": [
                {
                    "id": "D000009370",
                    "term": "Neoplasms by Histologic Type"
                },
                {
                    "id": "D000009369",
                    "term": "Neoplasms"
                },
                {
                    "id": "D000008232",
                    "term": "Lymphoproliferative Disorders"
                },
                {
                    "id": "D000008206",
                    "term": "Lymphatic Diseases"
                },
                {
                    "id": "D000007160",
                    "term": "Immunoproliferative Disorders"
                },
                {
                    "id": "D000007154",
                    "term": "Immune System Diseases"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M11220",
                    "name": "Lymphoma",
                    "asFound": "Lymphoma",
                    "relevance": "HIGH"
                },
                {
                    "id": "M12315",
                    "name": "Neoplasms by Histologic Type",
                    "relevance": "LOW"
                },
                {
                    "id": "M11225",
                    "name": "Lymphoproliferative Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M11203",
                    "name": "Lymphatic Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M10206",
                    "name": "Immunoproliferative Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M10200",
                    "name": "Immune System Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "T3543",
                    "name": "Lymphosarcoma",
                    "asFound": "Lymphoma",
                    "relevance": "HIGH"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC04",
                    "name": "Neoplasms"
                },
                {
                    "abbrev": "BC15",
                    "name": "Blood and Lymph Conditions"
                },
                {
                    "abbrev": "BC20",
                    "name": "Immune System Diseases"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "Rare",
                    "name": "Rare Diseases"
                }
            ]
        },
        "interventionBrowseModule": {
            "browseLeaves": [
                {
                    "id": "M17360",
                    "name": "Vaccines",
                    "relevance": "LOW"
                },
                {
                    "id": "M412",
                    "name": "Heptavalent Pneumococcal Conjugate Vaccine",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                }
            ]
        }
    },
    "hasResults": false
}